UF CJC today announced it has received a $30,000 grant from Lumina Foundation to study the financial state of college newspapers during COVID-19.
The technique uses a harmless virus to help fight a harmful virus. In this case, the harmless virus is used to package and deliver a gene from SARS-CoV-2, the strain of coronavirus that causes COVID-19. The gene therapy vaccine can’t replicate on its own but is potent enough to trigger a beneficial, antivirus response from the immune system.
Alex Fox-Alvarez leads online small group rounds with UF veterinary students on the surgery clinical clerkship who now required to learn remotely.
Many Americans are facing troubling emotional and lifestyle consequences of the self-isolation necessitated by the novel coronavirus pandemic. Lack of...
A new University of Florida epidemiological study finds that while children are less susceptible to COVID-19, when they do become infected they can be nearly 60% more likely than adults over 60 to infect exposed family members.
Members in UF’s Warren B. Nelms Institute, CISE and ECE are developing an affordable wearable device that indicates appropriate social distancing.
A comparatively small but crucial piece of the massive rollout efforts designed to get the new Pfizer-BioNTech COVID-19 vaccine from...
UF Department of Urban and Regional Planning Professor Ruth Steiner presented ideas pertaining to urban design in the COVID-19 era.
For many of us, the COVID-19 pandemic has brought plenty of novelty to our lives, like wearing masks and physical distancing. One aspect, though, gave financial economists déjà vu, and it’s looking a lot like 2008.
John Lednicky's past decades of inquiry into coronaviruses have positioned him as one of UF’s go-to experts on the coronavirus.
The mortality rate of the COVID-19 pandemic has altered the standard process of drug development, amplifying the need for lifesaving treatment and marking the start of the sprint toward a cure or gold standard treatment.
UF investigators participate in the first study to determine that the CoronaVac vaccine is 50% effective at preventing COVID-19 in Manaus, Brazil where the P.1 variant is widespread.